Cargando…

A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial

BACKGROUND: Previous pharmacokinetic trials suggested that 40 mg subcutaneous enoxaparin once daily provided inadequate thromboprophylaxis for intensive care unit patients. Critically ill patients with acute kidney injury are at increased risk of venous thromboembolism and yet are often excluded fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Sian, Zincuk, Aleksander, Larsen, Ulla Lei, Ekstrøm, Claus, Toft, Palle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061539/
https://www.ncbi.nlm.nih.gov/pubmed/24925372
http://dx.doi.org/10.1186/1745-6215-15-226
_version_ 1782321511263109120
author Robinson, Sian
Zincuk, Aleksander
Larsen, Ulla Lei
Ekstrøm, Claus
Toft, Palle
author_facet Robinson, Sian
Zincuk, Aleksander
Larsen, Ulla Lei
Ekstrøm, Claus
Toft, Palle
author_sort Robinson, Sian
collection PubMed
description BACKGROUND: Previous pharmacokinetic trials suggested that 40 mg subcutaneous enoxaparin once daily provided inadequate thromboprophylaxis for intensive care unit patients. Critically ill patients with acute kidney injury are at increased risk of venous thromboembolism and yet are often excluded from these trials. We hypothesized that for critically ill patients with acute kidney injury receiving continuous renal replacement therapy, a dose of 1 mg/kg enoxaparin subcutaneously once daily would improve thromboprophylaxis without increasing the risk of bleeding. In addition, we seek to utilize urine output prior to discontinuing dialysis, and low neutrophil gelatinase-associated lipocalin in dialysis-free intervals, as markers of renal recovery. METHODS/DESIGN: In a multicenter, double-blind randomized controlled trial in progress at three intensive care units across Denmark, we randomly assign eligible critically ill adults with acute kidney injury into a treatment (1 mg/kg enoxaparin subcutaneously once daily) or control arm (40 mg enoxaparin subcutaneously once daily) upon commencement of continuous renal replacement therapy. We calculated that with 133 patients in each group, the study would have 80% power to show a 40% reduction in the relative risk of venous thromboembolism with 1 mg/kg enoxaparin, at a two-sided alpha level of 0.05. An interim analysis will be conducted after the first 67 patients have been included in each group. Enrolment began in March 2013, and will continue for two years. The primary outcome is the occurrence of venous thromboembolism. Secondary outcomes include anti-factor Xa activity, bleeding, heparin-induced thrombocytopenia, filter lifespan, length of stay, ventilator free days, and mortality. We will also monitor neutrophil gelatinase-associated lipocalin and urine volume to determine whether they can be used as prognostic factors for renal recovery. DISCUSSION: Critically ill unit patients with acute kidney injury present a particular challenge in the provision of thromboprophylaxis. This study hopes to add to the growing evidence that the existing recommendation of 40 mg enoxaparin is inadequate and that 1 mg/kg is both safe and effective for thromboprophylaxis. In addition, the study seeks to identify predictors of renal recovery allowing for the proper utilization of resources. TRIAL REGISTRATION: EU Clinical Trials Register: EudraCT number: 2012-004368-23, 25 September 2012.
format Online
Article
Text
id pubmed-4061539
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40615392014-06-19 A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial Robinson, Sian Zincuk, Aleksander Larsen, Ulla Lei Ekstrøm, Claus Toft, Palle Trials Study Protocol BACKGROUND: Previous pharmacokinetic trials suggested that 40 mg subcutaneous enoxaparin once daily provided inadequate thromboprophylaxis for intensive care unit patients. Critically ill patients with acute kidney injury are at increased risk of venous thromboembolism and yet are often excluded from these trials. We hypothesized that for critically ill patients with acute kidney injury receiving continuous renal replacement therapy, a dose of 1 mg/kg enoxaparin subcutaneously once daily would improve thromboprophylaxis without increasing the risk of bleeding. In addition, we seek to utilize urine output prior to discontinuing dialysis, and low neutrophil gelatinase-associated lipocalin in dialysis-free intervals, as markers of renal recovery. METHODS/DESIGN: In a multicenter, double-blind randomized controlled trial in progress at three intensive care units across Denmark, we randomly assign eligible critically ill adults with acute kidney injury into a treatment (1 mg/kg enoxaparin subcutaneously once daily) or control arm (40 mg enoxaparin subcutaneously once daily) upon commencement of continuous renal replacement therapy. We calculated that with 133 patients in each group, the study would have 80% power to show a 40% reduction in the relative risk of venous thromboembolism with 1 mg/kg enoxaparin, at a two-sided alpha level of 0.05. An interim analysis will be conducted after the first 67 patients have been included in each group. Enrolment began in March 2013, and will continue for two years. The primary outcome is the occurrence of venous thromboembolism. Secondary outcomes include anti-factor Xa activity, bleeding, heparin-induced thrombocytopenia, filter lifespan, length of stay, ventilator free days, and mortality. We will also monitor neutrophil gelatinase-associated lipocalin and urine volume to determine whether they can be used as prognostic factors for renal recovery. DISCUSSION: Critically ill unit patients with acute kidney injury present a particular challenge in the provision of thromboprophylaxis. This study hopes to add to the growing evidence that the existing recommendation of 40 mg enoxaparin is inadequate and that 1 mg/kg is both safe and effective for thromboprophylaxis. In addition, the study seeks to identify predictors of renal recovery allowing for the proper utilization of resources. TRIAL REGISTRATION: EU Clinical Trials Register: EudraCT number: 2012-004368-23, 25 September 2012. BioMed Central 2014-06-13 /pmc/articles/PMC4061539/ /pubmed/24925372 http://dx.doi.org/10.1186/1745-6215-15-226 Text en Copyright © 2014 Robinson et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Robinson, Sian
Zincuk, Aleksander
Larsen, Ulla Lei
Ekstrøm, Claus
Toft, Palle
A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial
title A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial
title_full A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial
title_fullStr A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial
title_full_unstemmed A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial
title_short A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial
title_sort feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (fbi): study protocol for a randomized controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061539/
https://www.ncbi.nlm.nih.gov/pubmed/24925372
http://dx.doi.org/10.1186/1745-6215-15-226
work_keys_str_mv AT robinsonsian afeasiblestrategyforpreventingbloodclotsincriticallyillpatientswithacutekidneyinjuryfbistudyprotocolforarandomizedcontrolledtrial
AT zincukaleksander afeasiblestrategyforpreventingbloodclotsincriticallyillpatientswithacutekidneyinjuryfbistudyprotocolforarandomizedcontrolledtrial
AT larsenullalei afeasiblestrategyforpreventingbloodclotsincriticallyillpatientswithacutekidneyinjuryfbistudyprotocolforarandomizedcontrolledtrial
AT ekstrømclaus afeasiblestrategyforpreventingbloodclotsincriticallyillpatientswithacutekidneyinjuryfbistudyprotocolforarandomizedcontrolledtrial
AT toftpalle afeasiblestrategyforpreventingbloodclotsincriticallyillpatientswithacutekidneyinjuryfbistudyprotocolforarandomizedcontrolledtrial
AT robinsonsian feasiblestrategyforpreventingbloodclotsincriticallyillpatientswithacutekidneyinjuryfbistudyprotocolforarandomizedcontrolledtrial
AT zincukaleksander feasiblestrategyforpreventingbloodclotsincriticallyillpatientswithacutekidneyinjuryfbistudyprotocolforarandomizedcontrolledtrial
AT larsenullalei feasiblestrategyforpreventingbloodclotsincriticallyillpatientswithacutekidneyinjuryfbistudyprotocolforarandomizedcontrolledtrial
AT ekstrømclaus feasiblestrategyforpreventingbloodclotsincriticallyillpatientswithacutekidneyinjuryfbistudyprotocolforarandomizedcontrolledtrial
AT toftpalle feasiblestrategyforpreventingbloodclotsincriticallyillpatientswithacutekidneyinjuryfbistudyprotocolforarandomizedcontrolledtrial